In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings. Key topics included:• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting. Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes and send us your challenging cases for future discussions! #CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer. Key topics included: The definition and characteristics of high-risk non-muscle invasive bladder cancer. Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment. The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach. Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy. Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes. Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology! #NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).  We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML. Key topics covered in this episode included: The mechanism of action of Ziftomenib as a menin inhibitor Study findings from KOMET-001 and patient response rates Management of side effects, including differentiation syndrome and QTc prolongation Comparison with other menin inhibitors like Revumenib Future directions for combination therapies and sequencing of treatments Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information.  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights. #Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients. Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:• The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC.• A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib.• Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity.• Clinical pearls for managing adverse events and optimizing patient care.• The significance of patient education and regular follow-ups in ensuring treatment adherence and safety.Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice! #ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into:• An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.• Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias.• Unique side effects associated with each TKI and strategies for dose optimization.• The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer. Episode Highlights: MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach. FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC. SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib. Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients. Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care.  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on practice-changing research and major conference highlights! #ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice. Episode Highlighted:•⁠  ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer.•⁠  ⁠STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities.•⁠  ⁠MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies.•⁠  ⁠FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma. Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms. #ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine

In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer. We dived deep into the most impactful studies, including: • MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has overall survival benefit in adjuvant HR+ settings.• Metastatic HR+ Disease: Insights on the latest data surrounding PIK3CA mutations, with results from the VIKTORIA1 trial with Gedatolisib, and evERA study with Giredestrant. • HER2+ Breast Cancer: A comprehensive look at the DESTINY trials, highlighting the efficacy of Trastuzumab Deruxtecan (TDXd) in both neoadjuvant, adjuvant and palliative settings.• Triple Negative Breast Cancer: The role of sacituzumab and Dato-DXd in the first-line treatment landscape. Join us as we unpack these complex studies, discuss clinical implications, and share practical insights for community oncologists. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #ESMO2025 #BreastCancer #MonarchE #NATALEE #DESTINYtrials #CDK4/6 #ADCs #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer. Join us as we discuss:• The importance of surgical staging and debulking surgery in ovarian cancer treatment.• The role of neoadjuvant chemotherapy and the significance of germline testing.• Current systemic treatment paradigms, including the use of PARP inhibitors and Bevacizumab.• Insights into the management of refractory disease and the latest options available for patients.• The impact of biomarker testing and the importance of understanding HRD status. Dr. Lewin shared her expertise on the latest clinical data, treatment strategies, and the implications of testing for patients and their families. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell to stay updated on our upcoming episodes, including our next discussion on endometrial cancer! #OvarianCancer #PARPinhibitors #GermlineTesting #GynOnc #OncologyBrothers #MaintenanceTherapy #PersonalizedMedicine

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care. Episode Highlights: ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs. Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS. Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab. IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes. Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers

Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC). We explored the latest treatment options, including:•⁠  ⁠Osimertinib•⁠  ⁠Amivantamab plus Lazertinib (based on the MARIPOSA trial)•⁠  ⁠Osimertinib plus chemotherapy (from the FLAURA2 trial) Listen in as we analyze real-life patient cases, focusing on a 58-year-old gentleman with CNS involvement and a 66-year-old woman experiencing disease progression after initial treatment. Dr. Singhi shared valuable insights on the importance of supportive care, the impact of treatment combinations, and the significance of repeat tissue profiling. Key topics covered:•⁠  ⁠The latest data from the MARIPOSA and FLAURA2 trials•⁠  ⁠Strategies for managing side effects and improving patient quality of life•⁠  ⁠The role of multidisciplinary teams in treatment planning•⁠  ⁠The importance of understanding resistance patterns in treatment decisions Whether you're a healthcare professional or simply interested in oncology, this episode is packed with essential information and expert perspectives.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from The Oncology Brothers! #EGFRNSCLC #Mariposa #Amivantamab #Osimertinib #FLAURA2 #OncologyBrothers #LungCancer

In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib. Key topics discussed include:•⁠  ⁠The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.•⁠  ⁠Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.•⁠  ⁠The importance of shared decision-making with patients regarding treatment options.•⁠  ⁠Insights into the latest clinical trial data and its implications for practice. Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies! #CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC

In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML). Join us as we dive into the essential aspects of CML treatment, including:•⁠  ⁠The importance of initial workup and bone marrow biopsy in diagnosing CML.•⁠  ⁠Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib.•⁠  ⁠Patient-centered decision-making and how to align treatment options with individual patient goals.•⁠  ⁠Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD).•⁠  ⁠The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities.•⁠  ⁠Insights into the role of transplant in accelerated and blast phases of CML. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights. #CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes

Welcome to the Oncology Brothers podcast! In this Challenging Cases episode, we take a deep dive into thrombocytopenia management—a common yet often perplexing topic in everyday hematology and oncology practice. We are joined by Dr. Ronak Mistry, hematologist at the University of Pennsylvania and co‑host of Fellows on Call, to walk through real‑world cases spanning ITP, anticoagulation with low platelets, and HIT. We covered essential topics such as:• Workup of thrombocytopenia and confirming the diagnosis of ITP• First‑ and second‑line ITP therapy—steroids, IVIG, TPO receptor agonists, and splenectomy• ⁠Managing anticoagulation in thrombocytopenic patients with cirrhosis and DVT• ⁠Step‑by‑step approach to suspected HIT in the inpatient setting• Rapid‑fire tips—transfusion thresholds, chemo‑related thrombocytopenia, and medication culprits Whether you’re a hematologist, oncologist, or internal medicine resident, this episode is packed with case‑based teaching points, practical pearls, and the latest guidance from ASH and NCCN for non‑malignant hematology. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don’t forget to like, subscribe, and tune in for more challenging case discussions, treatment strategies, and expert insights from the world of hematology and oncology! #Thrombocytopenia #HematologyPodcast #ITP #HIT #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025. Key topics included:• Overview of the IMforte study design and patient population• The role of lurbinectedin and atezolizumab as maintenance therapy• Significant improvements in progression-free survival (PFS) and overall survival (OS)• Management of side effects and the importance of prophylactic growth factors• Patient selection criteria for this new standard of care With a focus on bridging the gap between community and academia, this episode provides valuable insights for medical oncologists and patients alike. Tune in to learn how these advancements are changing the landscape of SCLC treatment and improving patient outcomes.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other discussions on recent approvals, treatment algorithms, and challenging cases. We are the Oncology Brothers! #IMforte #SCLC #Lurbinectedin #MaintenanceTherapy #ASCO2025 #OncologyBrothers #ES-SCLC

Welcome to the Oncology Brothers podcast! In this episode, we dive into the evolving landscape of neuroendocrine tumors (NETs) with guests Dr. Heloisa Soares, a medical oncologist, and Prof. Ken Herrmann, a nuclear medicine specialist. Together, we explored the role of Peptide Receptor Radionuclide Therapy (PRRT), imaging breakthroughs, and treatment sequencing to optimize outcomes for NET patients. We cover essential topics such as:•⁠ ⁠The role of Gallium-68 and Copper-64 DOTATATE PET imaging in diagnosis and planning•⁠ ⁠Second-line standard use of PRRT and emerging data for first-line therapy•⁠ ⁠Toxicities of PRRT—nausea, kidney toxicity, and bone marrow suppression•⁠ ⁠Balancing sequencing strategies in well-differentiated and higher-grade tumors•⁠ ⁠The critical role of multidisciplinary tumor boards in NET management•⁠ ⁠Future directions including PRRT retreatment and ongoing clinical trials Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology! #NeuroendocrineTumors #NETs #PRRT #OncologyBrothers #CancerTreatment #NuclearMedicine

Welcome to the Oncology Brothers podcast! In this episode we we deep into the complexities of venous thromboembolism (VTE) with Drs. Jennifer Vaughn and Nicolas Gallastegui Crestani from The Ohio State University. Join us as we explore real-life VTE scenarios, discussing both provoked and unprovoked events, treatment durations, and cancer-associated cases. We cover essential topics such as: •⁠  ⁠The workup for hypercoagulable states in young patients•⁠  ⁠Long-term anticoagulation strategies for high-risk individuals•⁠  ⁠The role of D-dimer and risk scores in decision-making•⁠  ⁠Management of anticoagulation in patients with cancer undergoing treatment•⁠  ⁠Rapid-fire scenarios including superficial vein thrombosis and portal vein thrombosis Whether you're a healthcare professional or simply interested in the latest in oncology and hematology, this episode is packed with valuable insights and practical guidance. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology! #VTE #Anticoagulation #DOACs #Hematology #MedEd #OncologyBrothers #Thrombosis #Clots #DVT #PE

In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma. We covered a wide range of topics, including:•⁠  ⁠The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation.•⁠  ⁠The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients.•⁠  ⁠Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808.•⁠  ⁠The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring.•⁠  ⁠The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors. Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights! #Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive deep into the world of neuroendocrine tumors (NETs) with renowned expert Dr. Thor Halfdanarson from the Mayo Clinic. Join us as we explore:•⁠  ⁠The critical factors in diagnosing NETs, including origin, grade, histological features, and Ki-67.•⁠  ⁠The importance of differentiating between functional and non-functional tumors and how this impacts treatment decisions.•⁠  ⁠Dr. Halfdanarson's treatment paradigm, including the use of somatostatin analogs, radioligand therapy, and other targeted treatments.•⁠  ⁠Monitoring strategies for patients, including the role of imaging and tumor markers like 5-HIAA and chromogranin.•⁠  ⁠Insights into the evolving role of immunotherapy and next-generation sequencing in managing high-grade neuroendocrine carcinomas. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information and practical insights. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on cutting-edge cancer treatments and expert opinions in the field of oncology!

Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Cancer 2025! We are joined by Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, to discuss three pivotal studies that are shaping the future of lung cancer treatment. In this episode, we covered:•⁠  ⁠FLAURA2 Trial: Discover the significant overall survival benefits of combining osimertinib with chemotherapy for patients with EGFR-positive non-small cell lung cancer, and how it compares to single-agent osimertinib.•⁠  ⁠HARMONi Trial: Explore the intriguing yet complex findings of a new bi-specific antibody targeting PD-1 and VEGF in patients with progressive EGFR-mutated disease, and the implications of its current negative results.•⁠  ⁠ALCHEMIST Trial: Learn about the role of crizotinib in the adjuvant setting for ALK-positive lung cancer and why it reinforces alectinib as the standard of care. Tune in for an insightful discussion on the latest advancements in precision medicine, the importance of ctDNA, and the evolving landscape of lung cancer treatment.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!